Kotagal Vikas, Bohnen Nicolaas I, Müller Martijn L T M, Frey Kirk A, Albin Roger L
Department of Neurology, University of Michigan, Ann Arbor, MI, USA.
Neurology Service and GRECC, VAAAHS, Ann Arbor, MI, USA.
J Parkinsons Dis. 2017;7(1):143-147. doi: 10.3233/JPD-160985.
Progression to Hoehn and Yahr (HY) stage 3 marks the transition to advanced disease staging and disability in Parkinson disease (PD).
OBJECTIVE/METHODS: We conducted a case-control study of 36 PD subjects at HY stage 2.5 or 3, with groups matched for gender, age, and disease duration. Positron Emission tomography (PET) imaging included dihydrotetrabenazine [11C]DTBZ and Pittsburgh Compound B [11C]PiB.
Subjects with HY 2.5 differed from HY 3.0 in mean cortical PiB distribution volume ratio (1.14 vs. 1.23; Wilcoxon two-sample Z = 2.36, p = 0.024) but not striatal DTBZ PET.
Cortical amyloid burden differentiates subjects below and at HY stage 3. These results suggest that cortical amyloid accumulation influences the transition from HY2.5 to HY3 and that cortical amyloidopathy may be a therapeutic target in PD.
进展至霍恩和亚尔（HY）3期标志着帕金森病（PD）进入疾病晚期和残疾阶段。
目的/方法：我们对36名处于HY 2.5期或3期的PD患者进行了一项病例对照研究，两组在性别、年龄和病程方面相匹配。正电子发射断层扫描（PET）成像包括二氢丁苯那嗪[11C]DTBZ和匹兹堡化合物B[11C]PiB。
HY 2.5期的患者与HY 3.0期的患者在平均皮质PiB分布体积比上存在差异（1.14对1.23；威尔科克森两样本Z = 2.36，p = 0.024），但纹状体DTBZ PET无差异。
皮质淀粉样蛋白负荷可区分HY 3期以下和处于HY 3期的患者。这些结果表明，皮质淀粉样蛋白积累影响从HY2.5到HY3的转变，并且皮质淀粉样变性可能是PD的一个治疗靶点。
